2010
Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro
Adam A, Montpas N, Keire D, Désormeaux A, Brown NJ, Marceau F, Westenberger B. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. Biomaterials 2010, 31: 5741-5748. PMID: 20427081, PMCID: PMC2896062, DOI: 10.1016/j.biomaterials.2010.03.074.Peer-Reviewed Original ResearchConceptsContact system activationAnaphylactoid reactionsOversulfated chondroitin sulfateSystem activationSevere anaphylactoid reactionPlasma contact systemHuman plasmaInflammatory peptidesChondroitin sulfateEnzyme inhibitorsBK releaseDrug AdministrationBradykininHeparinSignificant correlationDefinitive evidenceDextran sulfatePlasma dilutionActivationConclusionPatientsPathophysiologyKininsAdministrationPlasma
2005
The Kallikrein-Kinin System: Current and Future Pharmacological Targets
Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The Kallikrein-Kinin System: Current and Future Pharmacological Targets. Journal Of Pharmacological Sciences 2005, 99: 6-38. PMID: 16177542, DOI: 10.1254/jphs.srj05001x.Peer-Reviewed Original ResearchMeSH KeywordsAngioedemaAngiotensin-Converting Enzyme InhibitorsAnimalsAprotininBradykininBradykinin B2 Receptor AntagonistsCardiovascular DiseasesComplement C1 Inactivator ProteinsComplement C1 Inhibitor ProteinHumansInflammationKallikrein-Kinin SystemKallikreinsKidney DiseasesKininsNeprilysinPeptidyl-Dipeptidase APolymorphism, GeneticPyridinesRandomized Controlled Trials as TopicReceptor, Bradykinin B1Receptor, Bradykinin B2SerpinsThiazepinesConceptsKallikrein-kinin systemMultiple pharmacological interventionsPrecursors of kininsFuture pharmacological targetsProinflammatory effectsVasoactive kininsPharmacological interventionsCardiovascular propertiesPharmacological targetsComplement pathwayKininsActive kininsPathological processesPharmacological activitiesPlasma kallikreinMetabolic cascadeImportant metabolic pathwaysMetabolic pathwaysAntiproteases